Since the original report in 1992 and revised nomenclature in 2009, pseudocysts of the scalp and alopecic and aseptic nodules of the scalp (AANS), respectively, have been regarded as a new entity that is rare and not understood in its pathogenesis. We observed 26 cases of AANS. Except for the extent and severity of disease, we found no single feature that justifies distinguishing AANS as a nosologic entity in its own right from dissecting cellulitis of the scalp (DCS). The scarring alopecias represent a diverse group of disorders with the potential of permanent destruction of the pilosebaceous unit and hair loss. Within the maze of varied conditions leading to scarring alopecia, the most important is to keep a neat nosologic classification in mind, based both on morphology and a pathogenic understanding. We believe that AANS represents a minor form of DCS, so far predominantly observed in patients of non-African origin, and therefore, is a disease of follicular occlusion with a favorable prognosis.

Background: Oral isotretinoin has been used to treat acne for decades. Although the side effects of isotretinoin are mostly predictable, one less common side effect of isotretinoin use is hair loss, typically telogen effluvium. Objective: This study is a retrospective report on the development of alopecia in patients on isotretinoin therapy. Methods: To characterize these patients, they were further compared to other patients in the same time period who were prescribed isotretinoin and did not experience hair loss. Results: Of 6330 patients with hair loss, 48 had been prescribed isotretinoin at some time between 2013 and 2018. Of these 48 patients, hair loss occurred concurrently or within two years after taking isotretinoin in 19 patients. When compared to controls, patients who experienced hair loss from isotretinoin were older, had greater cumulative isotretinoin doses, and had longer durations of treatment. Conclusion: Although the exact mechanism of how retinoids affect hair loss is still unclear, our findings suggest dosage or duration of usage may be associated. This information may be useful in counseling patients who may be concerned about hair loss when considering isotretinoin treatment.

Aim: The aim of this study is to identify a new method to measure oil penetration into hair, compare penetration ability of two types of oil: Type 3 hair oil and coconut oil into the hair shaft and explore its correlation to a physical property of hair, tensile strength. Materials and Methods: The study utilizes the measurements of two parameters, thickness, and cohesive force to define penetration of oil. The hypothesis was that an increase in hair fiber thickness along with reduction in cohesive force would indicate higher penetration of oil into the hair strand. The tensile strength of hair was then determined by measuring the behavior of treated hair strands while an axial stretching load was applied. Results: In experiment of hair thickness measurement, there was a significant increase in the hair fiber thickness post oil application in both the test oils as compared to baseline (untreated control). However, this increase was higher in hair swatches treated with Type 3 hair oil. For cohesive force measurement, significantly lower force was required for hair swatches treated with Type 3 hair oil when compared to coconut oil. For tensile strength, both test oils exhibited increase versus baseline but increase in tensile strength was significantly more with type 3 hair oil when compared to coconut oil. Conclusions: The present study shows that conjoint assessment of hair thickness and cohesive force post oil application can be a suitable method to indicate the extent of oil penetration into the hair. Overall, the study indicated the positive influence of oil penetration on hair strength.

Tofacitinib has been reported to activity in the recovery of alopecia areata (AA) in several reports, mainly from Western countries. We report the case of a young Indian boy with resistant AA who was treated with tofacitinib-based therapy. Improvements in terms of hair regrowth were observed within 6–8 weeks of treatment with oral tofacitinib 2.5 mg BID tablets, and the hair regrowth was nearly complete by 5 months. There were no associated side effects and the treatment with tofacitinib was well-tolerated.

Transient rectangular alopecia after endovascular embolization (TRAEE) is considered a specific form of radiodermatitis that is probably underreported in the literature. We present a case series of four patients from our hospital describing dermoscopic and histopathologic findings. Dermoscopic findings overlap with those of alopecia areata; therefore, TRAAE may be misdiagnosed without a precise history. Histopathology analysis of one of our cases showed different characteristics from the only report in the literature (high proportion of follicles in telogen phase). Initial reports considered that total radiation doses between 3 and 5 Gy produced TRAEE, whereas doses higher than 7Gy could trigger permanent alopecia. However, one of our patients exposed to a total dose of 7.6 Gy had complete hair regrowth.